Discovery of clinically approved agents that promote suppression of cystic fibrosis transmembrane conductance regulator nonsense mutations

American Journal of Respiratory and Critical Care Medicine

Volumn 194, Issue 9, 2016, Pages 1092-1103

  Mutyam, Venkateshwar ^a   Du, Ming ^b   Xue, Xiaojiao ^b   Keeling, Kim M ^b   Lucile White, E ^c   Robert Bostwick, J ^c   Rasmussen, Lynn ^c   Liu, Bo ^a   Mazur, Marina ^d   Hong, Jeong S ^d,e   Libby, Emily Falk ^d   Liang, Feng ^f   Shang, Haibo ^f   Mense, Martin ^f   Suto, Mark J ^c   Bedwell, David M ^b,d   Rowe, Steven M ^a,d,e,g  

^a University of Alabama at Birmingham   (United States)

^b University of Alabama at Birmingham   (United States)

^c SOUTHERN RESEARCH INSTITUTE   (United States)

^d UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^e UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^f Cystic Fibrosis Foundation Therapeutics   (United States)

^g University of Alabama at Birmingham   (United States)

Author keywords

Clinical agents; Cystic fibrosis transmembrane conductance regulator; Premature termination codon mutations; Readthrough

Indexed keywords

AMINOBENZOIC ACID; ANTIBIOTIC G 418; COLCHICINE; COMPLEMENTARY DNA; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; DOXORUBICIN; ESCIN; FORSKOLIN; IVACAFTOR; LUMACAFTOR; OXIBENDAZOLE; PREDNICARBATE; PYRANORADINE TETRAPHOSPHATE; UNCLASSIFIED DRUG; CFTR PROTEIN, HUMAN; LUCIFERASE; STOP CODON;

ANIMAL CELL; ARTICLE; CHLORIDE CONDUCTANCE; CONTROLLED STUDY; CYSTIC FIBROSIS; DRUG EFFICACY; FISCHER 344 RAT; IN VITRO STUDY; NONHUMAN; NONSENSE MUTATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; RAT; REAL TIME POLYMERASE CHAIN REACTION; SHORT CIRCUIT CURRENT; STOP CODON; THYROID CELL; ANIMAL; CELL LINE; DRUG DEVELOPMENT; DRUG EFFECTS; GENETICS; HUMAN; METABOLISM; PRECLINICAL STUDY; PROCEDURES;

ANIMALS; CELL LINE; CODON, NONSENSE; CYSTIC FIBROSIS; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; DRUG DISCOVERY; DRUG EVALUATION, PRECLINICAL; HUMANS; LUCIFERASES; RATS, INBRED F344; REAL-TIME POLYMERASE CHAIN REACTION;

EID: 84994805543     PISSN: 1073449X     EISSN: 15354970     Source Type: Journal    
DOI: 10.1164/rccm.201601-0154OC     Document Type: Article

References (41)

1. Rowe SM, Miller S, Sorscher EJ. Cystic fibrosis. N Engl J Med 2005;352: 1992-2001.
2. Welsh MJ, Smith AE. Molecular mechanisms of CFTR chloride channel dysfunction in cystic fibrosis. Cell 1993;73:1251-1254.
3. Sloane PA, Rowe SM. Cystic fibrosis transmembrane conductance regulator protein repair as a therapeutic strategy in cystic fibrosis. Curr Opin Pulm Med 2010;16:591-597.
4. Keeling KM, Wang D, Conard SE, Bedwell DM. Suppression of premature termination codons as a therapeutic approach. Crit Rev Biochem Mol Biol 2012;47:444-463.
5. Keeling KM, Brooks DA, Hopwood JJ, Li P, Thompson JN, Bedwell DM. Gentamicin-mediated suppression of Hurler syndrome stop mutations restores a low level of a-L-iduronidase activity and reduces lysosomal glycosaminoglycan accumulation. Hum Mol Genet 2001;10:291-299.
6. James PD, Raut S, Rivard GE, Poon MC, Warner M, McKenna S, Leggo J, Lillicrap D. Aminoglycoside suppression of nonsense mutations in severe hemophilia. Blood 2005;106:3043-3048.
7. Clancy JP, Bebök Z, Ruiz F, King C, Jones J, Walker L, Greer H, Hong J, Wing L, Macaluso M, et al. Evidence that systemic gentamicin suppresses premature stop mutations in patients with cystic fibrosis. Am J Respir Crit Care Med 2001;163: 1683-1692.
8. Clancy JP, Rowe SM, Bebok Z, Aitken ML, Gibson R, Zeitlin P, Berclaz P, Moss R, Knowles MR, Oster RA, et al. No detectable improvements in cystic fibrosis transmembrane conductance regulator by nasal aminoglycosides in patients with cystic fibrosis with stop mutations. Am J Respir Cell Mol Biol 2007;37:57-66.
9. Wilschanski M, Yahav Y, Yaacov Y, Blau H, Bentur L, Rivlin J, Aviram M, Bdolah-Abram T, Bebok Z, Shushi L, et al. Gentamicin-induced correction of CFTR function in patients with cystic fibrosis and CFTR stop mutations. N Engl J Med 2003;349:1433-1441.
10. Wilschanski M, Famini C, Blau H, Rivlin J, Augarten A, Avital A, Kerem B, Kerem E. A pilot study of the effect of gentamicin on nasal potential difference measurements in cystic fibrosis patients carrying stop mutations. Am J Respir Crit Care Med 2000;161: 860-865.
11. Sermet-Gaudelus I, Renouil M, Fajac A, Bidou L, Parbaille B, Pierrot S, Davy N, Bismuth E, Reinert P, Lenoir G, et al. In vitro prediction of stop-codon suppression by intravenous gentamicin in patients with cystic fibrosis: a pilot study. BMC Med 2007;5:5.
12. Xue X, Mutyam V, Tang L, Biswas S, Du M, Jackson LA, Dai Y, Belakhov V, Shalev M, Chen F, et al. Synthetic aminoglycosides efficiently suppress cystic fibrosis transmembrane conductance regulator nonsense mutations and are enhanced by ivacaftor. Am J Respir Cell Mol Biol 2014;50:805-816.
13. Kerem E, Konstan MW, De Boeck K, Accurso FJ, Sermet-Gaudelus I, Wilschanski M, Elborn JS, Melotti P, Bronsveld I, Fajac I, et al. for the Cystic Fibrosis Ataluren Study Group. Ataluren for the treatment of nonsense-mutation cystic fibrosis: a randomised, double-blind, placebo-controlled phase 3 trial. Lancet Respir Med 2014;2: 539-547.
14. Gonzalez-Hilarion S, Beghyn T, Jia J, Debreuck N, Berte G, Mamchaoui K, Mouly V, Gruenert DC, Déprez B, Lejeune F. Rescue of nonsense mutations by amlexanox in human cells. Orphanet J Rare Dis 2012;7: 58.
15. Mutyam V, Du M, Liu B, Xue X, White EL, Bostwick R, Rasmussen L, Tower N, Bedwell DM, Rowe SM. A screen to identify clinically available agents that promote suppression of premature termination codons [abstract]. Pediatr Pulmonol 2014;298.
16. Mutyam V, Du M, Liu B, Xue X, White EL, Bostwick R, Rasmussen L, Suto M, Bedwell DM, Rowe SM. Identification of clinically approved agent that efficiently promotes the suppression of premature termination codons in CFTR nonsense mutations [abstract]. Pediatr Pulomonol 2015;273.
17. Liu X, Ory V, Chapman S, Yuan H, Albanese C, Kallakury B, Timofeeva OA, Nealon C, Dakic A, Simic V, et al. ROCK inhibitor and feeder cells induce the conditional reprogramming of epithelial cells. Am J Pathol 2012;180:599-607.
18. Rowe SM, Sloane P, Tang LP, Backer K, Mazur M, Buckley-Lanier J, Nudelman I, Belakhov V, Bebok Z, Schwiebert E, et al. Suppression of CFTR premature termination codons and rescue of CFTR protein and function by the synthetic aminoglycoside NB54. J Mol Med (Berl) 2011;89:1149-1161.
19. Grentzmann G, Ingram JA, Kelly PJ, Gesteland RF, Atkins JF. A dual-luciferase reporter system for studying recoding signals. RNA 1998; 4:479-486.
20. Sloane PA, Shastry S, Wilhelm A, Courville C, Tang LP, Backer K, Levin E, Raju SV, Li Y, Mazur M, et al. A pharmacologic approach to acquired cystic fibrosis transmembrane conductance regulator dysfunction in smoking related lung disease. PLoS One 2012;7: e39809.
21. Van Goor F, Hadida S, Grootenhuis PD, Burton B, Cao D, Neuberger T, Turnbull A, Singh A, Joubran J, Hazlewood A, et al. Rescue of CF airway epithelial cell function in vitro by a CFTR potentiator, VX-770. Proc Natl Acad Sci USA 2009;106:18825-18830.
22. Ramsey BW, Davies J, McElvaney NG, Tullis E, Bell SC, Drevinek P, Griese M, McKone EF, Wainwright CE, Konstan MW, et al.; VX08-770-102 Study Group. A CFTR potentiator in patients with cystic fibrosis and the G551D mutation. N Engl J Med 2011;365: 1663-1672.
23. Sirtori CR. Aescin: pharmacology, pharmacokinetics and therapeutic profile. Pharmacol Res 2001;44:183-193.
24. Van Goor F, Hadida S, Grootenhuis PD, Burton B, Stack JH, Straley KS, Decker CJ, Miller M, McCartney J, Olson ER, et al. Correction of the F508del-CFTR protein processing defect in vitro by the investigational drug VX-809. Proc Natl Acad Sci USA 2011;108: 18843-18848.
25. Schneider-Poetsch T, Ju J, Eyler DE, Dang Y, Bhat S, Merrick WC, Green R, Shen B, Liu JO. Inhibition of eukaryotic translation elongation by cycloheximide and lactimidomycin. Nat Chem Biol 2010;6:209-217.
26. Sermet-Gaudelus I, Stoven V, Annereau JP, Witko-Sarsat V, Reinert P, Guyot M, Descamps-Latscha B, Lallemand JY, Lenoir G. Interest of colchicine for the treatment of cystic fibrosis patients. Preliminary report. Mediators Inflamm 1999;8:13-15.
27. Santoro D, Postorino A, Costa S, Cristadoro S, Buemi M, Magazzù G. Renal amyloidosis in cystic fibrosis: role of colchicine therapy. Clin Kidney J 2014;7:81-82.
28. Auld DS, Thorne N, Maguire WF, Inglese J. Mechanism of PTC124 activity in cell-based luciferase assays of nonsense codon suppression. Proc Natl Acad Sci USA 2009;106:3585-3590.
29. McElroy SP, Nomura T, Torrie LS, Warbrick E, Gartner U, Wood G, McLean WH. A lack of premature termination codon read-through efficacy of PTC124 (Ataluren) in a diverse array of reporter assays. PLoS Biol 2013;11:e1001593.
30. Siebert U, Brach M, Sroczynski G, Berla K. Efficacy, routine effectiveness, and safety of horsechestnut seed extract in the treatment of chronic venous insufficiency. A meta-analysis of randomized controlled trials and large observational studies. Int Angiol 2002;21:305-315.
31. Pittler MH, Ernst E. Horse chestnut seed extract for chronic venous insufficiency. Cochrane Database Syst Rev 2012;11:CD003230.
32. Ji DB, Xu B, Liu JT, Ran FX, Cui JR. b-Escin sodium inhibits inducible nitric oxide synthase expression via downregulation of the JAK/STAT pathway in A549 cells. Mol Carcinog 2011;50: 945-960.
33. Dong YJ, Chao AC, Kouyama K, Hsu YP, Bocian RC, Moss RB, Gardner P. Activation of CFTR chloride current by nitric oxide in human T lymphocytes. EMBO J 1995;14:2700-2707.
34. Kamosinska B, Radomski MW, Duszyk M, Radomski A, Man SF. Nitric oxide activates chloride currents in human lung epithelial cells. Am J Physiol 1997;272:L1098-L1104.
35. Berger AL, Randak CO, Ostedgaard LS, Karp PH, Vermeer DW, Welsh MJ. Curcumin stimulates cystic fibrosis transmembrane conductance regulator Cl-channel activity. J Biol Chem 2005;280: 5221-5226.
36. Wang W, Bernard K, Li G, Kirk KL. Curcumin opens cystic fibrosis transmembrane conductance regulator channels by a novel mechanism that requires neither ATP binding nor dimerization of the nucleotide-binding domains. J Biol Chem 2007;282:4533-4544.
37. Zhang Y, Yu B, Sui Y, Gao X, Yang H, Ma T. Identification of resveratrol oligomers as inhibitors of cystic fibrosis transmembrane conductance regulator by high-throughput screening of natural products from Chinese medicinal plants. PLoS One 2014;9:e94302.
38. Chen L, Yu B, Zhang Y, Gao X, Zhu L, Ma T, Yang H. Bioactivity-guided fractionation of an antidiarrheal Chinese herb Rhodiola kirilowii (Regel) Maxim reveals (-)-epicatechin-3-gallate and (-)-epigallocatechin-3-gallate as inhibitors of cystic fibrosis transmembrane conductance regulator. PLoS One 2015;10: e0119122.
39. 21-dependent contraction by the saponoside escin in rat vena cava: implications in venotonic treatment of varicose veins. J Vasc Surg 2011;54:489-496.
40. Nickless A, Jackson E, Marasa J, Nugent P, Mercer RW, Piwnica-Worms D, You Z. Intracellular calcium regulates nonsense-mediated mRNA decay. Nat Med 2014;20:961-966.
41. Suter A, Bommer S, Rechner J. Treatment of patients with venous insufficiency with fresh plant horse chestnut seed extract: a review of 5 clinical studies. Adv Ther 2006;23:179-190.